The results, which were published in the Lancet on Thursday, are very encouraging for the safety and efficacy of orforglipron in people with type 2 diabetes, says Daniel Drucker, an endocrinologist at the University of Toronto, adding that he is awaiting further clinical trial results of the drug in people with obesity
Today I review PedsCases Approach to Pediatric Vomiting Part 2
The researchers then carried out a statistical test on this data to assess whether alopecia was reported more often in people taking the GLP-1 RA than would normally occur in the FAERS database as a whole (this is known as a disproportionality analysis)
It has the molecular formula CHNOS, a molecular weight of 5135.9 g/mol, and CAS number 901758-09-6
In the SOUL trial, oral semaglutide was evaluated for its CV effects in individuals aged 50 years with T2D and established ASCVD or CKD
Comment: Several commenters requested that CMS does not finalize the proposed changes to the Diagnostic Tests and Related Services APC series